Medical news and careers, clearly connected
CareZelo
English
Menu

Nuashonruithe sláinte poiblí

Sláinte phoiblíCeanada

Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026

Baxter Corporation reports its Procytox (cyclophosphamide) 200 mg powder for intravenous solution (DIN 02241797) will be discontinued on Dec 31, 2026, for business reasons. The discontinuation decision will not be reversed.

Cyclophosphamide is a standard chemotherapy drug — cancer care teams should plan the switch to another strength or product before Dec 31.

Discontinuation date: Dec 31, 2026 Gach spriocdháta

Fiafraigh faoin achoimre seo

Is AI a scríobh na freagraí bunaithe ar an achoimre seo agus d'fhéadfadh siad a bheith mícheart. Seiceáil an bunfhoinse sula ngníomhaíonn tú.

2 cheist saor in aisce in aghaidh an lae gan chuntas. Is féidir le baill ceisteanna a chur chomh minic agus is mian leo, saor in aisce.

Ní comhairle leighis, dhlíthiúil ná inimirce é seo. Coinnítear ceisteanna gan ainm chun ár n-achoimrí a fheabhsú.

Léigh an bunleagan

Foinse oifigiúil: Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026 (osclaítear i gcluaisín nua) — Health Product Shortages Canada

Tuairiscigh fadhb

Dlite i gceann 20 láSláinte phoiblíCeanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Foinse oifigiúil: Health Product Shortages Canada (osclaítear i gcluaisín nua)

Dlite i gceann 20 láSláinte phoiblíCeanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Foinse oifigiúil: Health Product Shortages Canada (osclaítear i gcluaisín nua)

Dlite i gceann 39 láSláinte phoiblíCeanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Foinse oifigiúil: Health Product Shortages Canada (osclaítear i gcluaisín nua)

Dlite i gceann 18 láSláinte phoiblíCeanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Foinse oifigiúil: Health Product Shortages Canada (osclaítear i gcluaisín nua)